Fibroblast Activation Protein Inhibitor-PET Imaging in Colorectal Cancer

Esther Strating; Anne van de Loo; Sjoerd Elias; Marnix Lam; Onno Kranenburg

doi:10.1016/j.cpet.2023.02.003

Fibroblast Activation Protein Inhibitor-PET Imaging in Colorectal Cancer

Esther Strating, Anne van de Loo, Sjoerd Elias, Marnix Lam^*, Onno Kranenburg^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

Abstract

Fibroblast activation protein inhibitor (FAPI)-PET imaging holds great promise for improving the clinical management of colorectal cancer. High fibroblast activation protein expression is particularly observed in lymph node metastases, in the aggressive Consensus Molecular Subtype 4, in peritoneal metastases, and in tumors that respond poorly to immunotherapy. We have defined six clinical dilemmas in the diagnosis and treatment of colorectal cancer, which FAPI-PET may help solve. Future clinical trials should include patients undergoing tumor resection, allowing correlation of FAPI-PET signals with in-depth histopathological, cellular, and molecular tissue analyses.

Original language	English
Pages (from-to)	325-335
Number of pages	11
Journal	PET Clinics
Volume	18
Issue number	3
Early online date	6 Apr 2023
DOIs	https://doi.org/10.1016/j.cpet.2023.02.003
Publication status	Published - Jul 2023

Keywords

Colorectal cancer
Fibroblast activation protein
Fibroblast activation protein inhibitor
Peritoneal metastases
PET

Access to Document

10.1016/j.cpet.2023.02.003

Cite this

@article{ba958df44a864d869dd182660a5b3d9c,

title = "Fibroblast Activation Protein Inhibitor-PET Imaging in Colorectal Cancer",

abstract = "Fibroblast activation protein inhibitor (FAPI)-PET imaging holds great promise for improving the clinical management of colorectal cancer. High fibroblast activation protein expression is particularly observed in lymph node metastases, in the aggressive Consensus Molecular Subtype 4, in peritoneal metastases, and in tumors that respond poorly to immunotherapy. We have defined six clinical dilemmas in the diagnosis and treatment of colorectal cancer, which FAPI-PET may help solve. Future clinical trials should include patients undergoing tumor resection, allowing correlation of FAPI-PET signals with in-depth histopathological, cellular, and molecular tissue analyses.",

keywords = "Colorectal cancer, Fibroblast activation protein, Fibroblast activation protein inhibitor, Peritoneal metastases, PET",

author = "Esther Strating and {van de Loo}, Anne and Sjoerd Elias and Marnix Lam and Onno Kranenburg",

year = "2023",

month = jul,

doi = "10.1016/j.cpet.2023.02.003",

language = "English",

volume = "18",

pages = "325--335",

journal = "PET Clinics",

issn = "1556-8598",

publisher = "W.B. Saunders",

number = "3",

}

TY - JOUR

T1 - Fibroblast Activation Protein Inhibitor-PET Imaging in Colorectal Cancer

AU - Strating, Esther

AU - van de Loo, Anne

AU - Elias, Sjoerd

AU - Lam, Marnix

AU - Kranenburg, Onno

PY - 2023/7

Y1 - 2023/7

N2 - Fibroblast activation protein inhibitor (FAPI)-PET imaging holds great promise for improving the clinical management of colorectal cancer. High fibroblast activation protein expression is particularly observed in lymph node metastases, in the aggressive Consensus Molecular Subtype 4, in peritoneal metastases, and in tumors that respond poorly to immunotherapy. We have defined six clinical dilemmas in the diagnosis and treatment of colorectal cancer, which FAPI-PET may help solve. Future clinical trials should include patients undergoing tumor resection, allowing correlation of FAPI-PET signals with in-depth histopathological, cellular, and molecular tissue analyses.

AB - Fibroblast activation protein inhibitor (FAPI)-PET imaging holds great promise for improving the clinical management of colorectal cancer. High fibroblast activation protein expression is particularly observed in lymph node metastases, in the aggressive Consensus Molecular Subtype 4, in peritoneal metastases, and in tumors that respond poorly to immunotherapy. We have defined six clinical dilemmas in the diagnosis and treatment of colorectal cancer, which FAPI-PET may help solve. Future clinical trials should include patients undergoing tumor resection, allowing correlation of FAPI-PET signals with in-depth histopathological, cellular, and molecular tissue analyses.

KW - Colorectal cancer

KW - Fibroblast activation protein

KW - Fibroblast activation protein inhibitor

KW - Peritoneal metastases

KW - PET

UR - http://www.scopus.com/inward/record.url?scp=85152466443&partnerID=8YFLogxK

U2 - 10.1016/j.cpet.2023.02.003

DO - 10.1016/j.cpet.2023.02.003

M3 - Review article

C2 - 37030984

SN - 1556-8598

VL - 18

SP - 325

EP - 335

JO - PET Clinics

JF - PET Clinics

IS - 3

ER -

Fibroblast Activation Protein Inhibitor-PET Imaging in Colorectal Cancer

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this